



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

August 2024





© 2024 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

August 2024

N = 7720



Health Authority	Male	Female	All
FRASER	1617	496	2113
INTERIOR	493	114	607
NORTHERN	169	84	253
VANCOUVER COASTAL	3231	444	3675
VANCOUVER ISLAND	885	168	1053
	6395	1306	7701
		Unknown/not stated:	19
		Total:	7720

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (August 2019 - August 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (August 2019 - August 2024)



Notes: Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month




1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (August 2019 - August 2024)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (August 2019 - August 2024)






1.6 Percent Distribution of Active Participants by CD4 Count
(August 2019 - August 2024)






1.7 Percent Distribution of Inactive Participants by CD4 Count (August 2019 - August 2024)






1.8 Active and Inactive Participants (August 2019 - August 2024)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
(August 2019 - August 2024)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (August 2019 - August 2024)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(August 2019 - August 2024)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (August 2019 - August 2024)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(August 2019 - August 2024)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (August 2019 - August 2024)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (August 2019 - August 2024)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(August 2019 - August 2024)






1.18 Baseline CD4 for Antiretroviral First Starts
(August 2019 - August 2024)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (August 2019 - August 2024)






1.20 Cumulative Resistance Testing Results by Resistance Category (August 2019 - August 2024)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (August 2019 - August 2024)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2024
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	2	0	2	0		2	<40	3
1988	33	4	0	4	1	480	4	<40	4
1989	31	44	1	45	18	535	43	<40	3
1990	30	46	1	47	23	590	47	<40	3
1991	30	33	3	36	13	560	32	<40	3
1992	30	49	4	53	20	655	49	<40	3
1993	29	108	14	122	62	565	114	<40	3
1994	27	66	11	77	41	560	73	<40	3
1995	27	119	18	137	71	580	127	<40	3
1996	26	287	46	333	150	585	283	<40	3
1997	23	248	27	275	146	600	252	<40	3
1998	23	169	34	203	108	560	184	<40	3
1999	23	144	37	181	105	570	164	<40	3
2000	23	106	24	130	72	575	119	<40	3
2001	23	101	24	125	66	585	116	<40	3
2002	21	110	18	128	70	580	118	<40	3
2003	21	132	26	158	90	595	145	<40	3
2004	20	134	37	171	94	650	153	<40	3
2005	19	165	42	207	117	680	192	<40	3
2006	18	155	35	190	105	650	173	<40	3
2007	17	221	40	261	161	700	248	<40	3
2008	16	262	56	318	191	650	283	<40	3
2009	15	285	55	340	190	650	302	<40	3
2010	14	243	64	307	183	630	277	<40	3
2011	13	299	66	365	200	720	318	<40	3
2012	12	252	66	318	172	750	280	<40	3
2013	11	242	62	304	172	735	271	<40	3
2014	10	260	44	304	162	765	275	<40	3
2015	9	251	42	293	168	695	263	<40	3
2016	8	227	48	275	152	625	231	<40	3
2017	7	192	34	226	128	695	195	<40	3
2018	6	170	44	214	128	775	192	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2024
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	5	208	42	250	154	740	216	<40	3
2020	4	154	51	205	133	770	176	<40	3
2021	3	174	32	206	115	660	179	<40	3
2022	2	245	47	292	196	700	265	<40	3
2023	1	271	62	333	222	600	312	<40	3
2024	0	219	52	271	228	555	264	<40	3
Total:		6397	1309	7706					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	7581	793	2051	<40	1320	650
FEB-2023	7521	807	1727	<40	1020	630
MAR-2023	7548	803	1974	<40	1215	640
APR-2023	7553	796	1761	<40	1084	630
MAY-2023	7592	786	1933	<40	1238	645
JUN-2023	7599	787	1841	<40	1098	640
JUL-2023	7577	806	1747	<40	1053	620
AUG-2023	7600	806	1814	<40	1041	630
SEP-2023	7609	797	1775	<40	1068	645
OCT-2023	7610	804	1887	<40	1152	620
NOV-2023	7612	798	1854	<40	1099	650
DEC-2023	7603	801	1549	<40	915	640
JAN-2024	7643	792	1973	<40	1171	650
FEB-2024	7647	784	1773	<40	1036	620
MAR-2024	7636	792	1681	<40	985	650
APR-2024	7671	786	1943	<40	1221	660
MAY-2024	7690	787	1880	<40	1065	660
JUN-2024	7691	784	1696	<40	1010	650
JUL-2024	7723	786	1807	<40	1005	610
AUG-2024	7720	782	1869	<40	1069	650

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	56	512
APR-2023	760	218	66	<40	47	560
MAY-2023	726	239	65	<40	48	430
JUN-2023	708	200	57	<40	39	460
JUL-2023	739	182	68	<40	50	565
AUG-2023	738	188	63	<40	40	595
SEP-2023	725	207	55	<40	41	540
OCT-2023	735	209	60	<40	46	625
NOV-2023	742	203	65	<40	46	515
DEC-2023	751	192	47	<40	35	473
JAN-2024	708	219	67	<40	49	520
FEB-2024	706	232	58	<40	41	560
MAR-2024	720	200	66	<40	46	565
APR-2024	702	228	67	<40	56	545
MAY-2024	699	219	57	<40	40	555
JUN-2024	712	196	59	<40	36	459
JUL-2024	700	199	54	<40	27	640
AUG-2024	709	203	68	<40	40	610

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2023	7550	734	20	10	193	143	40	14767
FEB-2023	7505	787	10	11	158	204	-45	14791
MAR-2023	7532	756	15	21	197	176	27	14825
APR-2023	7531	760	13	11	176	169	-1	14854
MAY-2023	7575	726	7	15	205	165	44	14898
JUN-2023	7577	708	14	17	168	165	3	14933
JUL-2023	7555	739	11	11	164	181	-22	14964
AUG-2023	7577	738	11	13	217	192	22	15009
SEP-2023	7579	725	14	5	179	163	2	15029
OCT-2023	7579	735	18	10	170	160	0	15060
NOV-2023	7578	742	18	9	182	171	-1	15096
DEC-2023	7574	751	14	13	169	169	-4	15129
JAN-2024	7614	708	16	11	204	158	40	15161
FEB-2024	7620	706	17	11	183	165	6	15193
MAR-2024	7616	720	12	15	181	185	-4	15228
APR-2024	7648	702	17	20	197	167	32	15274
MAY-2024	7671	699	12	16	191	171	23	15311
JUN-2024	7685	712	5	24	171	175	14	15353
JUL-2024	7705	700	16	10	184	157	20	15386
AUG-2024	7706	709	10	17	162	162	1	15419

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2023	721	6371	445	44	7581	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6318	429	39	7521	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6312	445	41	7548	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	765	6307	440	41	7553	10.13%	83.50%	5.83%	0.54%	100.00%
MAY-2023	802	6314	435	41	7592	10.56%	83.17%	5.73%	0.54%	100.00%
JUN-2023	821	6299	438	41	7599	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	844	6253	440	40	7577	11.14%	82.53%	5.81%	0.53%	100.00%
AUG-2023	866	6240	448	46	7600	11.39%	82.11%	5.89%	0.61%	100.00%
SEP-2023	881	6250	432	46	7609	11.58%	82.14%	5.68%	0.60%	100.00%
OCT-2023	899	6237	433	41	7610	11.81%	81.96%	5.69%	0.54%	100.00%
NOV-2023	920	6210	441	41	7612	12.09%	81.58%	5.79%	0.54%	100.00%
DEC-2023	938	6191	434	40	7603	12.34%	81.43%	5.71%	0.53%	100.00%
JAN-2024	954	6215	432	42	7643	12.48%	81.32%	5.65%	0.55%	100.00%
FEB-2024	974	6198	436	39	7647	12.74%	81.05%	5.70%	0.51%	100.00%
MAR-2024	993	6159	440	44	7636	13.00%	80.66%	5.76%	0.58%	100.00%
APR-2024	1003	6185	437	46	7671	13.08%	80.63%	5.70%	0.60%	100.00%
MAY-2024	1026	6191	434	39	7690	13.34%	80.51%	5.64%	0.51%	100.00%
JUN-2024	1035	6185	428	43	7691	13.46%	80.42%	5.56%	0.56%	100.00%
JUL-2024	1063	6189	434	37	7723	13.76%	80.14%	5.62%	0.48%	100.00%
AUG-2024	1084	6166	431	39	7720	14.04%	79.87%	5.58%	0.51%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2909 39%	1 2%	1935 26%	0 0%	14 0%	34 76%	3717 50%	9 20%	969 13%	41 91%	4561 61%
SEP-2023	2 10%	2902 39%	1 5%	1910 26%	0 0%	13 0%	15 75%	3746 50%	3 15%	954 13%	18 90%	4578 61%
OCT-2023	2 6%	2904 39%	1 3%	1895 25%	0 0%	14 0%	23 74%	3766 50%	6 19%	935 13%	29 94%	4573 61%
NOV-2023	1 3%	2891 39%	0 0%	1866 25%	0 0%	15 0%	27 77%	3783 51%	7 20%	918 12%	34 97%	4585 61%
DEC-2023	6 18%	2874 39%	4 12%	1831 25%	0 0%	13 0%	25 76%	3820 51%	3 9%	895 12%	27 82%	4595 62%
JAN-2024	9 29%	2881 38%	8 26%	1831 24%	0 0%	13 0%	21 68%	3867 52%	2 6%	890 12%	22 71%	4634 62%
FEB-2024	7 22%	2868 38%	4 13%	1795 24%	0 0%	13 0%	22 69%	3896 52%	3 9%	864 12%	25 78%	4641 62%
MAR-2024	2 6%	2845 38%	0 0%	1759 23%	0 0%	13 0%	30 86%	3927 52%	3 9%	844 11%	33 94%	4656 62%
APR-2024	10 22%	2844 38%	5 11%	1742 23%	0 0%	13 0%	34 74%	3969 53%	3 7%	843 11%	36 78%	4691 62%
MAY-2024	4 11%	2822 37%	1 3%	1706 23%	0 0%	12 0%	31 84%	4021 53%	2 5%	832 11%	33 89%	4737 63%
JUN-2024	2 5%	2818 37%	2 5%	1692 22%	0 0%	13 0%	36 86%	4051 54%	4 10%	801 11%	40 95%	4742 63%
JUL-2024	4 13%	2813 37%	1 3%	1667 22%	0 0%	13 0%	24 75%	4081 54%	4 13%	801 11%	28 88%	4768 63%
AUG-2024	2 6%	2797 37%	0 0%	1633 22%	0 0%	13 0%	29 88%	4106 54%	3 9%	784 10%	31 94%	4782 63%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	303 23%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	294 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	276 23%	3 100%	914 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	271 22%	0 0%	909 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	1 50%	273 23%	1 50%	893 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
NOV-2023	1 33%	260 22%	2 67%	890 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
DEC-2023	0 0%	248 21%	1 100%	876 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JAN-2024	0 0%	241 21%	3 100%	866 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
FEB-2024	0 0%	229 21%	0 0%	852 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAR-2024	0 0%	225 21%	1 100%	840 77%	0 0%	30 3%	0 0%	0 0%	0 0%	0 0%
APR-2024	0 0%	224 21%	3 100%	835 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAY-2024	0 0%	221 20%	1 100%	828 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUN-2024	1 50%	214 20%	1 50%	813 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUL-2024	0 0%	216 21%	0 0%	805 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
AUG-2024	0 0%	208 20%	0 0%	785 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	91 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	88 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	238 26%	2 100%	216 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%
NOV-2023	0 0%	242 26%	0 0%	209 23%	1 50%	88 9%	0 0%	219 24%	1 50%	173 19%
DEC-2023	1 50%	250 27%	0 0%	205 22%	0 0%	87 9%	0 0%	213 23%	1 50%	176 19%
JAN-2024	0 0%	250 27%	0 0%	200 22%	0 0%	83 9%	0 0%	208 23%	2 100%	181 20%
FEB-2024	0 0%	257 28%	0 0%	192 21%	0 0%	82 9%	0 0%	207 23%	0 0%	182 20%
MAR-2024	0 0%	260 28%	1 100%	190 21%	0 0%	80 9%	0 0%	205 22%	0 0%	181 20%
APR-2024	0 0%	261 29%	0 0%	190 21%	0 0%	82 9%	0 0%	203 22%	0 0%	180 20%
MAY-2024	0 0%	262 29%	0 0%	186 21%	0 0%	80 9%	0 0%	205 23%	0 0%	175 19%
JUN-2024	0 0%	262 29%	0 0%	182 20%	0 0%	79 9%	0 0%	198 22%	0 0%	172 19%
JUL-2024	0 0%	270 30%	0 0%	176 20%	0 0%	78 9%	0 0%	194 22%	1 100%	172 19%
AUG-2024	0 0%	272 31%	0 0%	174 20%	0 0%	78 9%	0 0%	187 21%	0 0%	171 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir											
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All										
JAN-2023	23	82%	3016	50%	0	0%	0	0%	5	18%	2492	41%	0	0%	269	4%	0	0%	21	0%	0	0%	302	5%
FEB-2023	18	75%	3040	50%	0	0%	0	0%	6	25%	2476	41%	0	0%	255	4%	0	0%	21	0%	0	0%	288	5%
MAR-2023	25	74%	3084	51%	0	0%	0	0%	5	15%	2482	41%	2	6%	259	4%	0	0%	20	0%	2	6%	291	5%
APR-2023	22	81%	3084	50%	0	0%	0	0%	4	15%	2498	41%	1	4%	258	4%	0	0%	18	0%	0	0%	274	4%
MAY-2023	28	67%	3138	51%	1	2%	3	0%	12	29%	2504	41%	1	2%	250	4%	0	0%	18	0%	0	0%	278	5%
JUN-2023	26	81%	3197	51%	0	0%	5	0%	6	19%	2509	40%	0	0%	248	4%	0	0%	18	0%	0	0%	267	4%
JUL-2023	25	83%	3218	52%	0	0%	5	0%	5	17%	2499	40%	0	0%	247	4%	0	0%	18	0%	0	0%	256	4%
AUG-2023	33	79%	3258	52%	0	0%	7	0%	6	14%	2495	40%	1	2%	245	4%	0	0%	18	0%	2	5%	253	4%
SEP-2023	15	79%	3289	52%	0	0%	8	0%	4	21%	2500	40%	0	0%	238	4%	0	0%	18	0%	0	0%	249	4%
OCT-2023	22	76%	3298	52%	0	0%	7	0%	7	24%	2523	40%	0	0%	241	4%	0	0%	18	0%	0	0%	248	4%
NOV-2023	27	82%	3327	53%	0	0%	9	0%	6	18%	2518	40%	0	0%	233	4%	0	0%	17	0%	0	0%	244	4%
DEC-2023	24	77%	3365	53%	0	0%	13	0%	7	23%	2506	40%	0	0%	226	4%	0	0%	16	0%	0	0%	237	4%
JAN-2024	20	65%	3419	53%	1	3%	16	0%	10	32%	2520	39%	0	0%	224	4%	0	0%	18	0%	0	0%	234	4%
FEB-2024	21	66%	3453	54%	0	0%	15	0%	10	31%	2516	39%	0	0%	219	3%	0	0%	18	0%	1	3%	231	4%
MAR-2024	30	88%	3498	54%	0	0%	17	0%	4	12%	2500	39%	0	0%	220	3%	0	0%	17	0%	0	0%	225	3%
APR-2024	34	76%	3546	55%	0	0%	17	0%	11	24%	2497	38%	0	0%	216	3%	0	0%	18	0%	0	0%	225	3%
MAY-2024	29	78%	3589	55%	0	0%	19	0%	8	22%	2488	38%	0	0%	213	3%	0	0%	15	0%	0	0%	222	3%
JUN-2024	36	88%	3618	55%	0	0%	21	0%	5	12%	2488	38%	0	0%	207	3%	0	0%	17	0%	0	0%	218	3%
JUL-2024	22	67%	3654	55%	1	3%	25	0%	6	18%	2502	38%	4	12%	212	3%	0	0%	17	0%	0	0%	213	3%
AUG-2024	29	88%	3692	56%	0	0%	26	0%	4	12%	2489	38%	0	0%	204	3%	0	0%	17	0%	0	0%	207	3%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2023	750	9.89	665	8.77	4728	62.37	718	9.47	649	8.56	71	0.94
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	706	9.30	644	8.48	4752	62.59	800	10.54	627	8.26	63	0.83
JUN-2023	675	8.88	625	8.22	4788	63.01	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.46	621	8.17	4773	62.80	864	11.37	632	8.32	67	0.88
SEP-2023	639	8.40	616	8.10	4793	62.99	879	11.55	617	8.11	65	0.85
OCT-2023	615	8.08	611	8.03	4808	63.18	897	11.79	618	8.12	61	0.80
NOV-2023	611	8.03	599	7.87	4799	63.05	918	12.06	624	8.20	61	0.80
DEC-2023	593	7.80	596	7.84	4808	63.24	936	12.31	614	8.08	56	0.74
JAN-2024	583	7.63	585	7.65	4857	63.55	952	12.46	609	7.97	57	0.75
FEB-2024	564	7.38	586	7.66	4861	63.57	971	12.70	609	7.96	56	0.73
MAR-2024	543	7.11	580	7.60	4846	63.46	991	12.98	618	8.09	58	0.76
APR-2024	538	7.01	570	7.43	4885	63.68	1000	13.04	621	8.10	57	0.74
MAY-2024	536	6.97	566	7.36	4905	63.78	1023	13.30	607	7.89	53	0.69
JUN-2024	526	6.84	556	7.23	4914	63.89	1033	13.43	606	7.88	56	0.73
JUL-2024	520	6.73	541	7.01	4943	64.00	1061	13.74	605	7.83	53	0.69
AUG-2024	506	6.55	537	6.96	4943	64.03	1082	14.02	602	7.80	50	0.65

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	11	1	3	1	1	4	325
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	11	1	2	3	2	3	260
AUG-2023	13	2	1	4	2	2	255
SEP-2023	5	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390
NOV-2023	9	1	1	0	2	4	575
DEC-2023	13	1	0	3	0	8	592
JAN-2024	11	2	2	2	1	3	287
FEB-2024	11	1	2	4	2	1	281
MAR-2024	15	3	2	1	2	5	440
APR-2024	20	0	4	6	1	9	364
MAY-2024	16	2	3	3	1	6	320
JUN-2024	24	1	1	10	4	8	360
JUL-2024	10	0	1	3	3	2	374
AUG-2024	17	3	2	4	3	4	330

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2023	12447	3802
FEB-2023	12435	3787
MAR-2023	12442	3786
APR-2023	12417	3752
MAY-2023	12425	3730
JUN-2023	12398	3692
JUL-2023	12425	3715
AUG-2023	12422	3697
SEP-2023	12409	3685
OCT-2023	12393	3661
NOV-2023	12379	3648
DEC-2023	12400	3656
JAN-2024	12410	3664
FEB-2024	12423	3671
MAR-2024	12455	3686
APR-2024	12480	3691
MAY-2024	12488	3688
JUN-2024	12498	3668
JUL-2024	12494	3664
AUG-2024	12483	3644

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved


Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7720
Aug-2024

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Aug-2024

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2024

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Aug-2024

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Aug-2024

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Aug-2024

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	12	12	*
	50+	32	49	*
	Total HSDA:	49	66	30
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	71	102	47	
OKANAGAN	0-19	*	*	0
	20-34	*	*	33
	35-49	*	*	89
	50+	*	*	226
Total HSDA:	468	632	348	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	238	330	182	
Total HA:		826	1130	607

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	80	81	*
	35-49	195	212	*
	50+	546	832	*
Total HA:		826	1130	607

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	163	226	114
Male	663	904	493

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	607	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	26	13
	5 years or more	14	10
	<5 years	9	7
	Total HSDA:	49	30
KOOTENAY BOUNDARY	10 years or more	51	32
	5 years or more	11	8
	<5 years	9	7
	Total HSDA:	71	47
OKANAGAN	10 years or more	302	221
	5 years or more	85	60
	<5 years	81	67
	Total HSDA:	468	348
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	142	110
	5 years or more	44	28
	<5 years	52	44
	Total HSDA:	238	182
Total HA:		826	607

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	521	376
	5 years or more	154	106
	<5 years	151	125
Total HA:		826	607

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	55	101	13	30
KOOTENAY BOUNDARY	76	139	19	41
OKANAGAN	242	1090	52	325
THOMPSON/CARIBOO/SHUSWAP	150	582	27	137
Total:	523	1912	111	533

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	132

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	47	48	37
	35-49	109	113	71
	50+	276	388	206
	Total HSDA:	439	556	321
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1174	1596	897
FRASER SOUTH	0-19	7	7	7
	20-34	141	144	116
	35-49	306	334	250
	50+	656	1005	522
	Total HSDA:	1110	1490	895
Total HA:		2723	3642	2113

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	17
	20-34	320	326	260
	35-49	782	840	604
	50+	1604	2459	1232
Total HA:		2723	3642	2113

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	649	836	496
Male	2074	2806	1617

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2113	53	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	278	205
	5 years or more	84	52
	<5 years	77	64
	Total HSDA:	439	321
FRASER NORTH	10 years or more	747	553
	5 years or more	209	168
	<5 years	218	176
	Total HSDA:	1174	897
FRASER SOUTH	10 years or more	673	532
	5 years or more	198	149
	<5 years	239	214
	Total HSDA:	1110	895
Total HA:		2723	2113

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1698	1290
	5 years or more	491	369
	<5 years	534	454
Total HA:		2723	2113

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	153	558	32	64
FRASER NORTH	265	1621	36	236
FRASER SOUTH	234	1877	46	518
Total:	652	4056	114	818

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	214
FRASER NORTH	734
FRASER SOUTH	483
Total:	1431

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		371	550
RICHMOND	20-34	31	32	24
	35-49	57	58	45
	50+	129	186	106
	Total HSDA:	217	276	175
VANCOUVER	0-19	8	8	7
	20-34	387	400	289
	35-49	1209	1353	821
	50+	2996	5458	2091
	Total HSDA:	4600	7219	3208
Total HA:		5188	8045	3675

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	11
	20-34	448	462	333
	35-49	1343	1494	926
	50+	3385	6077	2405
Total HA:		5188	8045	3675

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	579	970	444
Male	4609	7075	3231

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3675	56	670	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	261	207
	5 years or more	51	42
	<5 years	59	43
	Total HSDA:	371	292
RICHMOND	10 years or more	120	94
	5 years or more	37	29
	<5 years	60	52
	Total HSDA:	217	175
VANCOUVER	10 years or more	3309	2251
	5 years or more	694	493
	<5 years	597	464
	Total HSDA:	4600	3208
Total HA:		5188	3675

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3690	2552
	5 years or more	782	564
	<5 years	716	559
Total HA:		5188	3675

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	195	565	38	58
RICHMOND	49	332	10	107
VANCOUVER	707	11929	213	5457
Total:	951	12826	261	5622

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	63

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		367	540
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		141	196
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		846	1213
Total HA:		1354	1949	1053

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	105	113	70
	35-49	312	347	247
	50+	931	1483	730
Total HA:		1354	1949	1053

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	222	326	168
Male	1132	1623	885

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1053	57	600	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	239	194
	5 years or more	70	47
	<5 years	58	52
	Total HSDA:	367	293
NORTH VANCOUVER ISLAND	10 years or more	104	86
	5 years or more	26	19
	<5 years	11	11
	Total HSDA:	141	116
SOUTH VANCOUVER ISLAND	10 years or more	533	394
	5 years or more	160	121
	<5 years	153	129
	Total HSDA:	846	644
Total HA:		1354	1053

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	876	674
	5 years or more	256	187
	<5 years	222	192
Total HA:		1354	1053

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	210	957	68	204
NORTH VANCOUVER ISLAND	159	362	30	62
SOUTH VANCOUVER ISLAND	235	2036	43	608
Total:	604	3355	141	874

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	81
NORTH VANCOUVER ISLAND	50
SOUTH VANCOUVER ISLAND	128
Total:	259

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	7
	35-49	18	21	11
	50+	31	41	17
	Total HSDA:	57	70	35
NORTH WEST	20-34	*	5	*
	35-49	*	39	*
	50+	*	87	*
	Total HSDA:	83	131	65
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	204	310	153
Total HA:		344	511	253

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		344	511	253

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	117	180	84
Male	227	331	169

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	253	53	610	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	15
	5 years or more	9	5
	<5 years	17	15
	Total HSDA:	57	35
NORTH WEST	10 years or more	57	43
	5 years or more	12	9
	<5 years	14	13
	Total HSDA:	83	65
NORTHERN INTERIOR	10 years or more	124	98
	5 years or more	51	33
	<5 years	29	22
	Total HSDA:	204	153
Total HA:		344	253

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	212	156
	5 years or more	72	47
	<5 years	60	50
Total HA:		344	253

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	51	4	6
NORTH WEST	90	170	13	31
NORTHERN INTERIOR	129	520	26	197
Total:	258	741	43	234

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	6
NORTH WEST	27
NORTHERN INTERIOR	23
Total:	56

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	12	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	31	52	19
	THOMPSON/CARIBOO/SHUSWAP	27	57	19
	Total HA:	70	130	48
FRASER	FRASER EAST	35	52	27
	FRASER NORTH	49	93	40
	FRASER SOUTH	81	120	61
	Total HA:	165	265	128
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	29	56	26
	RICHMOND	6	12	5
	VANCOUVER	430	912	342
	Total HA:	465	980	373
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	48	84	38
	NORTH VANCOUVER ISLAND	16	31	12
	SOUTH VANCOUVER ISLAND	49	98	38
	Total HA:	113	213	88
NORTHERN	NORTH EAST	13	17	9
	NORTH WEST	39	75	29
	NORTHERN INTERIOR	71	123	59
	Total HA:	123	215	97
Total:		936	1803	734

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	337	641	264
Male	599	1162	470

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	734	54	550	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Monthly Report

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Monthly Report

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

